A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin

Phase 1 Completed 57 enrolled Hangzhou Sciwind Biosciences Co., Ltd.

Non-randomizedSequentialOpen-labelTreatment

This is a study of a drug-drug interaction between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin

Evaluation	Drug	Modality	Dose	Route
Subject	Digoxin	Other / unclassified	0.25 mg	Oral
Subject	Ecnoglutide	Protein / enzyme biologic	1.2 mg	Subcutaneous
Subject	Metformin	Small molecule	0.5 mg	Oral
Subject	Rosuvastatin	Small molecule	10 mg	Oral
Subject	Warfarin	Small molecule	2.5 mg	Oral

No indication recorded.